Wealth Enhancement Advisory Services LLC Purchases Shares of 18,952 Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Wealth Enhancement Advisory Services LLC purchased a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 18,952 shares of the company’s stock, valued at approximately $128,000.

Other hedge funds also recently added to or reduced their stakes in the company. Man Group plc purchased a new position in Recursion Pharmaceuticals in the fourth quarter valued at approximately $479,000. Rockefeller Capital Management L.P. increased its stake in Recursion Pharmaceuticals by 323.1% in the fourth quarter. Rockefeller Capital Management L.P. now owns 281,922 shares of the company’s stock valued at $1,906,000 after purchasing an additional 215,283 shares during the last quarter. Invesco Ltd. increased its stake in Recursion Pharmaceuticals by 54.6% in the fourth quarter. Invesco Ltd. now owns 178,619 shares of the company’s stock valued at $1,207,000 after purchasing an additional 63,068 shares during the last quarter. Norges Bank purchased a new position in Recursion Pharmaceuticals in the fourth quarter valued at approximately $23,429,000. Finally, Northern Trust Corp increased its stake in Recursion Pharmaceuticals by 18.4% in the fourth quarter. Northern Trust Corp now owns 2,394,511 shares of the company’s stock valued at $16,187,000 after purchasing an additional 371,886 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on RXRX. Leerink Partners cut their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Friday, February 28th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Morgan Stanley decreased their price target on shares of Recursion Pharmaceuticals from $8.00 to $5.00 and set an “equal weight” rating for the company in a research note on Monday. Finally, Needham & Company LLC decreased their price target on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, May 6th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $7.00.

Recursion Pharmaceuticals Stock Down 3.2%

Shares of Recursion Pharmaceuticals stock opened at $4.84 on Wednesday. The company has a market cap of $1.97 billion, a P/E ratio of -2.73 and a beta of 0.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.11 and a current ratio of 4.11. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36. The firm has a fifty day moving average of $4.91 and a two-hundred day moving average of $6.30.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.06). The firm had revenue of $14.75 million for the quarter, compared to analysts’ expectations of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The firm’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.39) EPS. On average, analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.